Dr. Reed Phillips: Protecting Pigs from PRRS | Ep. 143
Episode S2 ยท Ep 143 15 min 41s

Dr. Reed Phillips: Protecting Pigs from PRRS | Ep. 143

In this episode of The Swine Health Blackbelt Podcast, Dr. Reid Philips, Associate Director of Technical Marketing at Boehringer Ingelheim, discusses a crucial study evaluating the efficacy of a PRRS MLV vaccine against the PRRSV '144' L1C.5 variant. Dr. Philips explains the studyโ€™s design, key findings, and how the vaccine stands up to evolving strains. Listen now! "We saw a level of protection with the PRRS MLV vaccine in all those major measurable parameters: lung lesions, average daily weight gain, and viremia." ๐— ๐—ฒ๐—ฒ๐˜ ๐˜๐—ต๐—ฒ ๐—ด๐˜‚๐—ฒ๐˜€๐˜: Dr. Reid Philips https://www.linkedin.com/in/reid-philips-9b286113/ , DVM, is the Associate Director of Technical Marketing at Boehringer Ingelheim Animal Health USA, Inc. With over three decades of experience, Dr. Philips has significantly contributed to PRRS management strategies and vaccine development. After receiving his DVM from Iowa State University in 1981, he practiced in Iowa and Nebraska before joining Boehringer Ingelheim in 1994. His work focuses on developing and implementing field-based solutions for PRRS management. What you will learn: (00:00) Highlight (01:56) Introduction (02:24) Challenge trial (03:36) PRRS strains (06:11) Key parameters (07:20) Study findings (12:16) Viremia reduction (14:63) Closing thoughts The Swine Health Blackbelt Podcast is trusted and supported by innovative companies like: * Boehringer Ingelheim (https://www.boehringer-ingelheim.com/) - Farm Health Guardian (http://www.farmhealthguardian.com/) - Elanco (https://www.elanco.com/en-us) ๐—Ÿ๐—ถ๐˜€๐˜๐—ฒ๐—ป ๐—ผ๐—ป ๐—”๐—ฝ๐—ฝ๐—น๐—ฒ ๐—ฃ๐—ผ๐—ฑ๐—ฐ๐—ฎ๐˜€๐˜๐˜€, ๐—ฆ๐—ฝ๐—ผ๐˜๐—ถ๐—ณ๐˜† ๐—ผ๐—ฟ ๐—ฎ๐—ป๐˜† ๐—บ๐—ฎ๐—ท๐—ผ๐—ฟ ๐—ฝ๐—น๐—ฎ๐˜๐—ณ๐—ผ๐—ฟ๐—บ. Website: https://swinehealthblackbelt.com Instagram: https://www.instagram.com/swinecampus/ LinkedIn: https://www.linkedin.com/company/80692493

Community discussion